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AbstrAct
Objectives Serum testosterone (T) levels in men decline 
with age. Low T levels are associated with sarcopenia and 
frailty in men aged >80 years. T levels have not previously 
been directly associated with disability in older men. 
We explored associations between T levels, frailty and 
disability in a cohort of octogenarian men.
setting Data from all men from Life and Living in 
Advanced Age Cohort Study in New Zealand, a longitudinal 
cohort study in community-dwelling older adults.
Participants Community-dwelling (>80 years) adult men 
excluding those receiving T treatment or with prostatic 
carcinoma.
Outcomes measures Associations between baseline total 
testosterone (TT) and calculated free testosterone (fT), 
frailty (Fried scale) and disability (Nottingham Extended 
Activities of Daily Living scale (NEADL)) (baseline and 
24 months) were examined using multivariate regression 
and Wald’s χ2 techniques. Subjects with the lowest 
quartile of baseline TT and fT values were compared with 
those in the upper three quartiles.
results Participants: 243 men, mean (SD) age 83.7 (2.0) 
years. Mean (SD) TT=17.6 (6.8) nmol/L and fT=225.3 
(85.4) pmol/L. On multivariate analyses, lower TT 
levels were associated with frailty: β=0.41, p=0.017, 
coefficient of determination (R2)=0.10 and disability 
(NEADL) (β=−1.27, p=0.017, R2=0.11), low haemoglobin 
(β=−7.38, p=0.0016, R2=0.05), high fasting glucose 
(β=0.38, p=0.038, R2=0.04) and high C reactive protein 
(CRP) (β=3.57, p=0.01, R2=0.06). Low fT levels were 
associated with frailty (β=0.39, p=0.024, R2=0.09) but not 
baseline NEADL (β=−1.29, p=0.09, R2=0.09). Low fT was 
associated with low haemoglobin (β=−7.83, p=0.0008, 
R2=0.05) and high CRP (β=2.86, p=0.04, R2=0.05). 
Relationships between baseline TT and fT, and 24-month 
outcomes of disability and frailty were not significant.
conclusions In men over 80 years, we confirm an 
association between T levels and baseline frailty 
scores. The new finding of association between T levels 
and disability is potentially relevant to debates on T 
supplementation in older men, though, as associations 
were not present at 24 months, further work is needed.
IntrOductIOn
Serum testosterone (T) levels decline with 
age in healthy men, and although there may 
be some degree of cohort effect,1 it is gener-
ally accepted that this is a genuine age-re-
lated phenomenon that continues up to 
extreme longevity (age 90+) in populations 
studied.2–4 Decline in circulating T level is 
influenced by Leydig cell attrition and other 
pathological and physiological factors that 
affect the hypothalamic–pituitary–testicular 
axis.5 Though the clinical and functional 
consequences of this decline are less clear, 
age-related low T levels have been associ-
ated with an increased prevalence of sarco-
penia5 6 and with the frailty syndrome.5 7 8 
These latter associations have, however, been 
demonstrated mainly in those under 80 years 
of age, with few studies in men over the age 
of 80 years.7 8 Further, there has been little 
research directed at examining a poten-
tial association of T levels with long-term 
disability in older men, although some (not 
all) studies that examined activity levels, falls 
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subjects.
 ► Employed trained personnel and validated measures.
 ► Extends information on associations of serum 
testosterone levels to very old men.
 ► Associations reported cannot be assumed to be 
causal.
 ► Possible selection bias, as some study subjects 
declined blood tests.
 ► No longitudinal analysis of serum testosterone 
levels.
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and quality of life scales against T levels have implied a 
possible relationship with disability.9–13
There remains uncertainty about the role of T in late 
life. Supplementation for older men with low T levels 
has not necessarily been beneficial to sarcopenia and 
frailty. Though short-term supplementation studies 
have confirmed improvements in muscle bulk/lean 
body mass, muscle power (in some studies but not all), 
physical and function tests/activity levels,5 14–18 the clin-
ical value of these improvements is unknown. Further, 
despite evidence that short-term treatment does not 
produce prolonged benefit,17 there are no really long-
term studies. Very few studies were found with a dura-
tion of 3 years: one of these demonstrated no effect of 
T on muscle strength.5 16 Another reported an increase 
in grip strength19 A very recent study, also over 3 years, 
showed that T supplementation improved some (not 
all) measures of muscle strength, but that any beneficial 
effect ‘appeared to wane over time’.20 Important concerns 
about longer-term safety remain, most particularly with 
regard to known or (in the absence of definitive studies) 
potential behavioural and other side effects (erythrocy-
tosis, cardiovascular events and possible increased risk of 
prostate cancer) of T supplementation,5 21 though more 
recent extensive reviews have been relatively reassuring 
regarding potential medium-term and long-term poten-
tial cardiovascular and prostate cancer risks.22 23
Life and Living in Advanced Age Cohort Study in New 
Zealand (LiLACS NZ): Te Puāwaitanga o Ngā Tapuwae 
Kia Ora Tonu is a population-based cohort study of Māori 
(indigenous people of New Zealand) and non-Māori of 
advanced age, including those in long-term care. In the 
present paper, we examine whether serum T levels at 
baseline are associated with validated outcome measures 
of frailty and of extended activities of daily living (EADL) 
in men enrolled in LiLACS NZ, and to assess any asso-
ciation of baseline hormone levels with change in these 
outcome measures 2 years later. Our rationale was to add 
to the limited knowledge around the association between 
T levels and frailty in very old men and to examine rela-
tionships between T levels and EADL.
MethOds
subjects and study methods
The full methodology of the LiLACS NZ is described 
elsewhere.24 Briefly, two cohorts of similar size, Māori 
and non-Māori, were enrolled. Potential participants 
were those born between 1 January and 31 December 
1925 (aged 85 years in 2010) for non-Māori and between 
1 January 1920 and 31 December 1930 (aged 80–90 
years in 2010) for Māori. People meeting these criteria 
and living within the Lakes (excluding Taupo) region 
or Bay of Plenty District Health Board areas during the 
2010 enrolment year were eligible. The Northern X 
Regional Ethics Committee of New Zealand granted 
ethics approval for the longitudinal study in December 
2009 (NTX/09/09/088), and written informed consent 
was obtained from all participants. Considerable efforts 
were made to ascertain as complete a sample as possible 
of those eligible and kaupapa Māori methods25 were used 
to enable Māori participation. For the current study, all 
male participants who gave a blood sample (optional) 
were potentially eligible except those with known diag-
nosis of prostatic carcinoma or those receiving T supple-
mentation. Given the wide-scoped methodology of the 
LiLACS NZ study, no separate power analysis for T levels 
was conducted.
Baseline measures (wave 1) were collected by trained 
interviewers and research nurses26 using standardised 
techniques: a structured face-to-face standardised ques-
tionnaire, a health assessment and blood tests and a 
review of general practice medical records for diagnosed 
medical conditions. Blood samples (cholesterol, glucose, 
haemoglobin, high-sensitive C reactive protein (CRP) and 
total testosterone (TT)) were collected by a registered 
nurse or local laboratory service as a morning (fasting) 
sample at wave 1. TT levels were measured by competi-
tive ELISA in duplicate (R&D systems, Minneapolis, USA) 
with detection limit of 0.041 ng/mL. The manufacturer's 
reported intra-assay and interassay coefficients of varia-
tion were 4.0% and 6.8%, respectively. Free testosterone 
(fT) was calculated.27 Smoking status and estimated alco-
holic drinks per annum were ascertained by self-report. 
Blood pressure (digital device), height (stadiometer) 
and weight (Tanita scales) were measured by a trained 
research nurse at baseline. The mean of the last two of 
three blood pressure measures was used. The Charlson 
Index of Comorbidity28 was calculated from a combina-
tion of self-report, general practitioner medical record 
review and from hospital records from the previous 
12 months using ICD-10 codes.29 Further details are avail-
able from the authors on request.
Participants were reinterviewed annually: this report 
uses the baseline data (wave 1) and that from two 
follow-ups (waves 2 and 3) completed at 12 and 24 
months.
Outcomes
The following provides a brief résumé of protocols, 
which are reported in detail elsewhere.24 Fried Frailty 
Index30 was measured with variables collected as 
follows: weakness grip strength measured by lowest 20% 
(by gender, ethnic group, body mass index (BMI)); 
poor endurance—from the question “During the past 
four weeks (have you) had a lot of energy none of the 
time or little of the time”; slowness of walking speed 
from 3 metre walk test of the Short Physical Perfor-
mance Battery protocol—the slowest 20% (by gender, 
ethnic group, height); low activity by Physical Activity 
Scale for the Elderly scores—the lowest 20% by gender 
and ethnic group; unintentional weight loss ≥5 kg in 
previous 6 months. The Fried Index is scored 0 to 5, a 
score of 0 corresponding to a ‘robust’ individual, scores 
of 1 or 2 indicating a ‘prefrail’ individual and scores of 3 
or higher indicating a ‘frail’ individual.
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The Nottingham Extended Activities of Daily Living 
Index (NEADL)31 was collected for all subjects. The SF-12 
Mental Health Component summary subscore (MHC) 
and Physical Health Component subscore (PHC) were 
used to assess health-related quality of life (HRQOL).32 
NEADL is scored between 0 and 22 points, higher scores 
indicating less disability. PHC and MHC are scored from 
0 to 100, higher scores indicating better quality of life.
statistical methods
Age was treated as a continuous variable. Both total and 
fT measures were dichotomised into lowest quartile versus 
the upper three quartiles.33 The association between 
TT and fT and outcomes of NEADL, SF-12 PHC, MHC 
and the Fried scale was assessed using age-adjusted and 
ethnicity-adjusted generalised linear models. All models 
assumed normal T distributions. These were checked 
against models controlling for potential confounders 
including smoking status, cholesterol, haemoglobin, 
blood pressure, alcoholic drinks per annum and Charlson 
Index. Change in NEADL, SF-12 PHC, MHC and the 
Fried scale over 1 and 2 years of follow-up were also 
modelled, with change in outcome (NEADL, frailty or 
HRQOL) as the dependent variable and T level at base-
line as the independent variable. Models were controlled 
for age, ethnicity initially (multivariate model) and then 
smoking, cholesterol, haemoglobin, blood pressure and 
drinking in an extended model. To consider differences 
between men who did, versus did not, provide a blood 
sample we used 40 iterations of multiple imputation for 
the NEADL complex model, the PHC complex model, 
the MHC complex model and the Fried complex model.
results
Subjects (table 1) comprised 390 men with mean (SD) 
age of 83.7 (2.2) years at baseline. Of these 147 were inel-
igible: 82 completed core questions only which did not 
include blood tests, 29 consented but did not give a blood 
sample and 24 declined blood tests on their consent form. 
A further 12 were excluded; 9 because of known prostatic 
carcinoma, 2 being treated with cyproterone acetate and 
1 with another prostate injury.
Overall, at baseline, 243 (mean (SD) age of 83.7 (2.0) 
years, 83 Māori and 160 non-Māori) were included. 
Those consenting to blood tests were healthier and less 
frail than those that did not: of those not giving a blood 
sample, 13% were in residential care compared with 1% 
of those that did give a sample (p<0.0001); of those giving 
a blood sample, 97% showered independently compared 
with 88% of those not giving a sample (p=0.011) and of 
those who gave a blood sample, 5% died within 12 months 
compared with 8% of those not giving blood (p=0.20). 
More Māori declined blood sampling (59% Māori, 42% 
non-Māori declined, p<0.0001).
Mean (SD) Charlson Index was 6.52 (5.92). Ten per 
cent were frail (scoring 3+ on the Fried Index), 37% 
were prefrail and 53% were not frail. Mean NEADL score 
was 17.8 (SD 3.4) (maximum score=22, indicating no 
disability). Over time 203 of the 243 completed the 1-year 
follow-up, 171 completed the 2-year follow-up.
As described, the Fried Index is a five-point scale with 
1 point given for each of five markers of frailty. No one 
in our sample scored 5 and most scored 0. The models 
presented treat the Fried score as a continuous variable, 
although the ordinal was a better fit (and gave a p value 
for fT of 0.031 and TT of 0.021). Beta (β) in this model 
is the estimated log OR of scoring in the Fried 0 vs >0, 
but is also the estimated log OR of scoring in the Fried 0 
or 1 vs >1, etc (the link is log because the Fried Index is 
modelled as having a negative binomial distribution). At 
baseline, the mean (SD) of TT was 17.6 (6.8) nmol/L and 
of fT was 225.3 (85.4) pmol/L. The lowest quartiles were 
below 13.3 nmol/L for TT and below 175.1 pmol/L for 
fT). On analyses adjusting for age and ethnic group, lower 
TT levels were independently associated with both frailty 
(Fried score; F-statistic=9.72, p=0.0021) and disability 
(NEADL score; F-statistic=6.14, p=0.014) at baseline.
TT level was also positively associated with haemo-
globin level (p=0.0016) and negatively associated with 
fasting glucose (p=0.038) and CRP (p=0.010). fT was also 
positively associated with haemoglobin (p=0.0008) and 
negatively associated with CRP (p=0.04). TT or fT was 
not associated with ethnicity (Māori/non-Māori), total 
cholesterol, blood pressure, BMI, waist circumference, 
alcohol consumption, tobacco smoking or quality of life 
at baseline. Low fT levels were associated with Fried score 
(p=0.0034) but not NEADL (p=0.07).
In multivariate models (tables 2 and 3), when 
controlling for age, ethnicity, smoking status, total choles-
terol level, haemoglobin, blood pressure, alcoholic drinks 
per annum and Charlson score, lower TT remained inde-
pendently associated with Fried score (p=0.017) and 
with NEADL (p=0.017); low fT was independently asso-
ciated with Fried score (p=0.024) but not with NEADL 
(p=0.093).
Longitudinal analyses showed no association of either 
baseline TT or fT levels with the change in either Fried 
score or NEADL levels over time. The wave 2 interview 
was on average 363 (SD 31) days and the wave 3 interview 
734 (SD 40) days, respectively, after the wave 1 interview. 
Sensitivity analyses were conducted using 40 iterations of 
multiple imputation; conclusions did not change.
dIscussIOn
The age-related decline in serum T levels in healthy men 
is now generally recognised.5 Though we do not have a 
younger group for comparison, our results add to the 
currently limited literature extending evidence of low 
T levels beyond the age of 80 years. However, the lack 
of a fully validated normative range for T in men over 
80 years is due to an imperfect understanding about 
late-onset hypogonadism—a very recently established 
range being based on assessments in approximately 300 
individuals in total.34 Hence the current study adds to 
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Table 1 Demographics of sample
Total testosterone Free testosterone
TotalLowest quartile Other quartiles Lowest quartile Other quartiles
Age (years) 83.8 (1.8) 83.6 (2.1) 83.8 (1.8) 83.6 (2.0) 83.7 (2.0)
Height (m) 1.7 (0.06) 1.7 (0.06) 1.7 (0.06) 1.7 (0.06) 1.7 (0.06)
Weight (kg) 81.6 (16.1) 79.7 (12.1) 81.7 (15.8) 79.7 (12.2) 80.2 (13.2)
Body mass index (kg/m2) 28.3 (5.2) 27.7 (4.2) 28.4 (5.2) 27.7 (4.2) 27.9 (4.5)
Haemoglobin (g/L) 132.4 (16.8) 139.7 (15.0) 132 (16.6) 139.9 (15.0) 137.9 (15.8)
Serum cholesterol (mmol/L) 4.62 (0.97) 4.66 (0.95) 4.67 (0.97) 4.64 (0.96) 4.65 (0.96)
Serum triglycerides (mmol/L) 1.42 (0.62) 1.31 (0.79) 1.39 (0.63) 1.32 (0.79) 1.34 (0.75)
High density lipoprotein (mmol/L) 1.40 (0.34) 1.40 (0.34) 1.41 (0.33) 1.40 (0.35) 1.40 (0.34)
Low density lipoprotein (mmol/L) 2.57 (0.85) 2.67 (0.81) 2.63 (0.85) 2.65 (0.81) 2.64 (0.82)
Glycated haemoglobin (mmol/L) 39.5 (12.4) 37.9 (7.9) 39 (12.3) 38.1 (8.0) 38.3 (9.2)
Serum glucose (mmol/L) 5.93 (1.73) 5.53 (1.01) 5.85 (1.50) 5.55 (1.13) 5.63 (1.23)
Systolic blood pressure (BP) (mm Hg) 144.3 (23.0) 146.6 (21.5) 142.7 (22.9) 147.1 (21.4) 146 (21.9)
Diastolic BP (mm Hg) 80.8 (14.0) 82.2 (12.8) 80.2 (14.4) 82.4 (12.6) 81.9 (13.1)
Estimated number of alcoholic drinks 
per annum
222.1 (245.8) 266.3 (280.0) 235.2 (242.0) 262.2 (281.6) 255.8 (272.4)
Number of medications 6.53 (3.41) 4.72 (3.42) 6.11 (3.15) 4.86 (3.55) 5.16 (3.50)
Māori (%) 19 (31.2) 64 (35.2) 20 (32.8) 63 (34.6) 83 (34.2)
Currently smokes (%) 4 (6.6) 15 (8.2) 4 (6.6) 15 (8.2) 19 (7.8)
Congestive heart failure (%) 19 (31.2) 40 (22.0) 18 (29.5) 41 (22.5) 59 (24.3)
Had CVA (%) 14 (23.0) 42 (23.1) 13 (21.3) 43 (23.6) 56 (23.1)
Peripheral vascular disease (%) 11 (18.0) 24 (13.2) 12 (19.7) 23 (12.6) 35 (14.4)
Hypertensive (%) 52 (85.3) 161 (88.5) 53 (86.9) 160 (87.9) 213 (87.7)
Asthma (%) 11 (18.0) 12 (6.6) 10 (16.4) 13 (7.1) 23 (9.5)
Osteoporosis (%) 4 (6.6) 6 (3.3) 5 (8.2) 5 (2.8) 10 (4.1)
Chronic lung disease (%) 14 (23.0) 33 (18.1) 14 (23.0) 33 (18.1) 47 (19.3)
Diabetes (%) 14 (23.0) 25 (13.7) 14 (23.0) 25 (13.7) 39 (16.1)
Dementia (%) 1 (1.6) 7 (3.9) 1 (1.6) 7 (3.9) 8 (3.3)
Rheumatoid arthritis (%) 9 (14.8) 24 (13.2) 8 (13.1) 25 (13.7) 33 (13.6)
Osteoarthritis (%) 23 (37.7) 47 (25.8) 23 (37.7) 47 (25.8) 70 (28.8)
Coronary artery disease (%) 36 (59.0) 76 (41.8) 33 (54.1) 79 (43.4) 112 (46.1)
Atrial fibrillation (%) 16 (26.2) 50 (27.5) 17 (27.9) 49 (26.9) 66 (27.2)
Anaemia (%) 28 (45.9) 43 (23.6) 28 (45.9) 43 (23.6) 71 (29.2)
a relatively small body of knowledge on this topic. The 
clinical and functional significance of this age-related 
decline, and any need for possible T supplementation 
to prevent, ameliorate or treat its putative effects remain 
controversial. The debate in this area has thus far largely 
focused on the association of T decline with frailty.7 8 12 35 
Although some authors have also addressed quality of 
life and physical performance, including a possible asso-
ciation of T decline with disability,9–14 as far as we are 
aware ours is the first study to demonstrate that lower T 
is associated with disability in a population in advanced 
age unselected for organ-specific diseases.28 35 36 Despite 
overall T levels in our sample being a little higher than 
those previously reported for previous studies in older 
men,1–4 our34 results clearly indicate a strong relationship 
between lower TT levels at baseline and baseline disability 
measured on a well-validated instrumental activities of 
daily living scale, as well as hinting at (p=0.07) a similar 
relationship between calculated baseline fT levels and 
baseline disability scores. There was also a strong asso-
ciation between baseline T and baseline frailty scores. 
Given that frailty is a strong predictor of disability and 
other adverse outcomes28 this is perhaps unsurprising, 
but it does potentially add some weight (despite our 
demonstrated lack of relationship between baseline T 
levels and frailty or disability measures at 24 months) to 
the argument for (long-term) trials of T supplementation 
in older frail men with low or low/normal T levels17 21; 
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amelioration, postponement, prevention or treatment of 
disability has potential for greater and more immediate 
personal (patient) and societal benefit than amelioration, 
postponement, prevention or treatment of frailty. This 
may be particularly so for some frail men in whom small 
gains in strength and function may be adequate to main-
tain or restore independence—though what criteria are 
employed to identify such men remain to be elucidated.36 
There has been recent interest in T supplementation in 
the treatment of unexplained anaemia in older men.37 
Given that chronic anaemia may contribute to frailty, our 
confirmation of the recognised association of T levels and 
haemoglobin levels is potentially important.
The association between lower T levels and disability 
was observed at baseline, and no prediction of change in 
function related to T level was observed. A similar discrep-
ancy between cross-sectional and longitudinal findings 
regarding T and frailty (but not disability) was revealed 
in a study by Cawthon et al,38 who thus hypothesised that 
either: (1) there is no relationship between T levels and 
frailty, that is, that their cross-sectional associations were 
in fact a chance association. In the current study (like that 
of Cawthon et al) we believe that we have included most 
potential covariates, and we thus agree with Cawthon 
that this explanation is not likely, though of course, as 
Cawthon also acknowledged, we cannot exclude such a 
possibility in what is purely an observational study; (2) T 
is truly related to frailty and disability, but that the longi-
tudinal associations do not reach statistical significance 
because of limited power to detect an association due 
to inadequate sample size (the sample size at 24 months 
being smaller than the baseline sample).
Though age-related sarcopenia, frailty and subsequent 
disability are well recognised even in otherwise healthy 
older men,26 chronic disease and especially multiple 
chronic comorbidity, is a major risk factor for both frailty 
and disability. Chronic diseases are known to be associated 
with low T levels.5 28 35 36 T levels may fall further during 
acute exacerbations of these chronic conditions in rela-
tion to severity of exacerbation.36 Although our subjects 
were medically well (ie, not institutionalised or hospital-
ised and not acutely ill) at the time of T estimation, their 
levels of comorbidity were relatively high, with on average 
five conditions.39 There is thus need for studies of T levels 
and disability in healthy older men, as opposed to a more 
representative sample of a population such as LiLACS NZ. 
Whether trials of T supplementation, as discussed above, 
should, at least initially, be confined to otherwise healthy 
older men, or should include older men with (multiple) 
comorbidity35 is a more complex issue. Further adding to 
the complexity is the as yet unresolved possibility, despite 
recent relatively reassuring data, that T supplementation 
carries the risk of major adverse effects.
Our study was part of a well-conducted, representative 
population cohort study in which subjects were care-
fully characterised. It employed well-validated measures 
administered by trained personnel. The associations we 
demonstrated between T levels and glucose, haemoglobin 
and CRP levels confirm those recognised previously and 
are thus reassuring.2
Our study also has weaknesses. First, as discussed above, 
though we attempted to allow for this statistically, the 
effect of comorbidity on the relationship between T levels 
and disability (and frailty) cannot be fully elucidated, and 
the associations reported cannot be regarded as causal. 
Second, many of our potentially eligible subjects did not 
contribute a blood sample. Although this increased the 
selection bias of our sample, it may have militated against 
any effect of multiple comorbidity, as those consenting to 
blood tests were a healthier sample than those not. Third, 
as all of our subjects were aged 85 years (non-Māori) or 
80–90 years (Māori), we were unable to examine any 
differential age-related cohort effect on T levels. This has, 
however, been previously well characterised by others.1–4 
Fourth (and similarly), we assessed T levels at only one 
time-point, thus precluding any longitudinal analysis of T 
levels—though again this has been previously character-
ised.2 3 We were not able to demonstrate that baseline TT 
and fT predict change in frailty or disability measure over 
2 years. Finally, it would have been helpful to have had T 
measures from a comparator group of young men from 
the same local population, but the study methodology 
precluded this.
The lack of a fully validated normative range in older 
men for T is due to the lack of understanding about 
late-onset hypogonadism, hence this study adds to a 
small body of knowledge on this topic. Those with lower 
T levels relative to their peers were significantly more 
likely to be frail and disabled in advanced age. Further 
research is needed to confirm our findings, to examine 
these relationships in a (selected) sample of healthy men 
of advanced age and to examine the longitudinal value 
of a baseline measurement of (or decline in) serum T in 
the prediction of frailty and disability. Should these rela-
tionships be confirmed this would add weight to the argu-
ment for assessing the potential benefits and hazards of 
T supplementation in both healthy older men and older 
men with comorbidity.
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